

To the Copenhagen Stock Exchange
Announcement No. 05-07 / Copenhagen 26 March 2007

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

Notice of the Annual General Meeting

Notice is hereby given that the Annual General Meeting of TopoTarget A/S will be held on:

Wednesday 11 April 2007 at 4.00 pm

The Annual General Meeting will be held at:

Axelborg, Vesterbrogade 4A, DK-1620 Copenhagen V, Denmark

The agenda for the Annual General Meeting is as follows:

1. The Board of Directors' report on the company's activities during the past year.
2. Presentation of the revised annual report with auditor's report for adoption and notification of discharge to the Board of Directors.
3. Resolution on application of profits or covering of losses as per the adopted annual report.
4. Election of Board Members and alternates, if any.
5. Election of state authorised public accountant.
6. Other proposals from the Board of Directors and/or shareholders.

Re 6 - Authorisation to the Board of Directors to allow the company purchase own shares

The Board of Directors proposes that the Board of Directors according to the Companies Act section 48 is authorised to allow the company to purchase own shares within the 10% limit as set out in section 48. The shares can be purchased at a price corresponding to the listed price plus/minus 5% at the time of the purchase. The authorisation shall be applicable until and including the company's annual general meeting in 2008.

Re 6 - Authorisation to the Board of Directors to issue warrants.

The Board of Directors proposes that the Board of Directors until 1 March 2012 is authorised, at one or more times, to issue up to 1,000,000 warrants, each conferring a right to subscribe for 1 share of nominal DKK 1 in the company, and to implement the corresponding increase of the share capital. The warrants can be issued to employees, executive directors, board members, consultants and advisors to the company and its subsidiaries without pre-emptive subscription rights for the company's shareholders.



The exercise price for warrants which are issued pursuant to the authorisation shall at a minimum correspond to the market price of the company's shares on the date of issuance of the warrants. The other terms for the warrants issued pursuant to this authorisation shall be determined by the Board of Directors.

It is noted that the adoption of the proposals for amendments to the Articles of Association on the agenda requires that the resolution is approved by at least two thirds of the votes given and two thirds of the votes represented at the general meeting.

The agenda and the complete proposed resolutions will be available for inspection at the company's office c/o Symbion, Fruebjergvej 3, 2100 Copenhagen Ø not later than eight days before the Annual General Meeting, and will not later than eight days before the Annual General Meeting be sent to any recorded shareholder who has requested so.

Registered shareholders will receive a request form for an admission card. Shareholders, who are not registered, may request admission cards from TopoTarget's office on all weekdays (Saturdays excepted) in accordance with article 12 of the Articles of Association. Admission cards may also be ordered directly at www.topotarget.com.

TopoTarget will be serving light refreshments after the Annual General Meeting.

The annual report 2006 will be sent to registered shareholders on 28 March 2007.

TopoTarget A/S

For further information, please contact:

Dr. Peter Buhl Jensen	Telephone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22

Background information

About TopoTarget

TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to www.topotarget.com

